FDA Approvals in 2018 Recap!

We had 13 eye-related FDA approvals in 2018. Here is your quick rundown.

1. Dexycu – It’s a sustained-release one-time injection of dexamethasone in the anterior chamber after cataract surgery. More info here.
2. Systane Complete – This artificial tear gives relief to patients with evaporative dry eye, aqueous deficient dry eye, and/or a combo of both.
3. IDx-DR –  An artificial intelligence diagnostic system that analyzes fundus photos to determine if diabetic retinopathy is present. More info here.
4. Artificial Iris Implant – The first prosthetic iris for adults and children with congenital aniridia or other iris defects. More info here.
5. iStent Inject – It’s a Micro-Invasive Glaucoma Surgery (MIGS) device and is the second generation of the iStent which was approved in 2012. More info here.
6. Refresh Repair – An over-the-counter drop that contains osmoprotectants and is focused around the hyperosmotic surface found in dry eye. More info here.
7. Alleye – A mobile app indicated for the screening and monitoring of macular degeneration. More info here.
8. Cequa – A prescription eye drop indicated to increase tear production in patients with dry eye. It’s cyclosporin 0.09%. More info here.
9. Inveltys – It’s loteprednol etabonate ophthalmic suspension 1% and is approved for the treatment of postoperative inflammation and pain following ocular surgery. More info here.
10. Oxervate – It contains cenegermin which is a recombinant form of human nerve growth factor. It’s approved for the treatment of neurotrophic keratitis. More info here.
11. Xelpros – It’s latanoprost 0.005%.  Xelpros is the only form of latanoprost that is not formulated with benzalkonium chloride (BAK). More info here.
12. Yutiq – It’s a fluocinolone acetonide intravitreal implant approved for patients with chronic noninfectious posterior uveitis. More info here.
13. Dextenza – It’s a dexamethasone insert, placed through the punctum into the canaliculus and delivers dexamethasone to the ocular surface for up to 30 days. More info here.

Get in Touch


Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts